Deep-dive on Pharma Research Products (214450.KQ): the KOSDAQ company behind Rejuran PDRN skin boosters, riding the global K-beauty aesthetic injectable wave.
Eight Korean stocks cleared 5–7 independent quant screeners in the week of Apr 16, 2026 — from SK Hynix to a little-known electrical-equipment compounder.
Pearl Abyss (263750.KQ) just crossed 5 million copies of Crimson Desert. We break down why 7.5M is now a floor, what the free update roadmap really means for long-tail monetization, and where the real re-rating triggers lie.
NextBiomedical investment analysis. Nexpowder hemostatic agent in commercialization phase across 30+ countries via Medtronic. Nexphere-F absorbable embolization microsphere in US pivotal trial with FDA Breakthrough Device Designation. 2025 revenue KRW 16.5B, OP loss KRW 735M. HS code export data-based Q1 2026 estimates and analyst target price reverse-engineering.